Return
Pulmonary diffusion abnormalities in patients with inflammatory bowel disease: A longitudinal study
H
B
A
M
D
F
B
L
A
S
DOI:10.1177/17562848261475935.png)
Abstract
En 中文
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>
Impaired diffusing capacity of the lung for carbon monoxide (DL
<jats:sub>CO</jats:sub>
) has been frequently described among patients with inflammatory bowel diseases, but longitudinal data of DL
<jats:sub>CO</jats:sub>
impairment and its association with IBD activity remain unclear.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Objectives</jats:title>
<jats:p>
To describe the longitudinal report of prevalence and clinical characteristics of chronic DL
<jats:sub>CO</jats:sub>
impairment among patients with IBD reporting respiratory symptoms.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Design</jats:title>
<jats:p>We conducted a prospective single-center study including consecutive patients with confirmed IBD and respiratory symptoms.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Patients underwent longitudinal evaluation with chest CT scans and pulmonary function tests.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>
Among 75 patients with DL
<jats:sub>CO</jats:sub>
measurements, 12 (16%) showed persistently reduced DL
<jats:sub>CO</jats:sub>
over a median follow-up of 26.9 [IQR 24.9–30.6] months. Median DL
<jats:sub>CO</jats:sub>
was 63.4% of predicted value. All patients had mild or inactive IBD and were on biologics. Imaging abnormalities were mild and did not explain the DL
<jats:sub>CO</jats:sub>
reduction.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>
Chronic DL
<jats:sub>CO</jats:sub>
impairment was observed in 16.0% of IBD patients and no obvious association with clinically active IBD was observed in this selected symptomatic cohort.
</jats:p>
</jats:sec>
Journal
T
IF:
3.4
Papers:
1.5K
Citations:
3.9K
